Addus HomeCare’s Q2 earnings report drops Monday, showing steady but slowing growth—revenue up 7.7% YoY, slightly below expectations but beating EPS estimates. Analysts project similar modest growth for the quarter, down from last year’s 21.8% surge, and the company’s track record of missing revenue targets adds intrigue. Meanwhile, rivals BrightSpring and Chemed both outperformed, with Chemed’s stock rising 4.2%. Despite the mixed signals, Addus shares have climbed 9.2% in a month, trading near $115 against an average analyst price target of $133.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
